Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TCB008
- Development stage
- Phase 2
- Lead developer
- TC BioPharm
- Modality
- Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
TCB008 (also known as OmnImmune) is an investigational allogeneic unmodified cell therapy composed of activated and expanded gamma delta (γδ) T cells derived from healthy donors. These CD3+ lymphocytes express the Vγ9Vδ2 T-cell receptor and are expanded ex vivo before being purified and formulated for infusion. The therapy is designed to boost the immune response in patients with relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)/AML by leveraging the innate and adaptive immune properties of γδ T cells, which can distinguish between healthy and diseased tissue. Developed by TC BioPharm, this product is currently under clinical investigation in phase 1b/2 trials for AML/MDS[1][3][5][7].
- Brand names
- OmnImmune
- Other names
- tcb-002tcb002tcb 002tcb008tcb-008tcb 008
02
Targets
MICB (Major histocompatibility complex class i-related protein B)NECTIN2 (Nectin cell adhesion molecule 2)ULBP (UL16-binding protein)BTN3A1 (Butyrophilin 3A1/2A1 complex)
Beyond the preview
Go deeper on TCB008.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TCB008.